Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 5Squamous Intraepithelial Lesions 2Papillomavirus Infections 2Leukemia, Myeloid, Acute 2HIV Infections 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Anus Neoplasms 2Solitary Fibrous Tumor, Pleural 1Smoldering Multiple Myeloma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostate Adenocarcinoma 1Precancerous Conditions 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Mouth Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Malignant mesenchymal tumor 1Lung Neoplasms 1Liposarcoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leiomyosarcoma 1

Interventions

Lenalidomide 8Dexamethasone 6Calcium Dobesilate 6Melphalan 3elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Peripheral Blood Stem Cell Transplantation 2Bortezomib 2pomalidomide 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1Watchful Waiting 1Urination 1Transplantation, Autologous 1Stem Cell Transplantation 1Receptors, Interleukin-6 1Observation 1Nivolumab 1Metformin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1IPH-2101 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoldering Multiple Myeloma × Watchful Waiting × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡